Drip-and-Ship Model for Thrombectomy in Stroke Patients with Large-Vessel Occlusion

Abstract

<b><i>Background:</i></b> Previous studies have demonstrated the efficacy of the “drip-and-ship” model in acute ischemic stroke (AIS) patients treated with intravenous (IV) thrombolysis. We investigated and report the outcomes of the safety and efficacy of the “drip-and-ship” model in AIS patients with acute large-vessel occlusion (LVO) in the anterior circulation who underwent endovascular treatment. <b><i>Methods:</i></b> A total of 92 AIS patients with LVO who underwent endovascular treatment enrolled from April 2017 to July 2018 at a single academic comprehensive stroke center (CSC) were included. Patients were divided into 2 groups: a front-door group (directly admitted to the CSC) and a drip-and-ship group (transferred to the CSC from other hospital). Logistic regression model was used to evaluate the functional outcome, mortality, and symptomatic intracranial hemorrhage (sICH) at 90 days. <b><i>Results:</i></b> After adjusting for age, gender, occlusion site, National Institutes of Health Stroke Scale (NIHSS) score, and other potential covariates, we did not see difference in modified Rankin Scale (mRS) score between the 2 groups at 90 days. The rate of excellent functional outcome (defined as mRS 0–1) in the drip-and-ship group is lower than the front-door group (<i>p</i> = 0.017); however, functional outcomes (defined as mRS 0–2) have no difference (<i>p</i> = 0.117). There was no significant difference in sICH (<i>p</i> = 0.909) and mortality (<i>p</i> = 0.319) between the 2 groups. <b><i>Conclusions:</i></b> The “drip-and-ship” model has the potential to be a feasible model for patients with LVO in the anterior circulation to undergo endovascular treatment. Further large-scale prospective studies are warranted to confirm these findings.